4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model

Acute GVHD: Pathophysiology, 3-Phase Model & Organ Staging

Core Clinical Principle: Acute Graft-versus-Host Disease (aGVHD) represents an immunological attack launched by immunocompetent donor-derived T-lymphocytes against genetically disparate host tissues following allogeneic hematopoietic cell transplantation (HCT). While the graft-versus-tumor (GVT) effect is beneficial in preventing malignant relapse, uncontrolled acute GVHD is a leading cause of non-relapse mortality (NRM). Accurate diagnosis relies on recognizing the classic target organ triad—Skin, Gastrointestinal (GI) Tract, and Liver—and applying standardized organ staging criteria before initiating prompt systemic immunosuppression.

---

1. Classical Criteria and Chronological Classification

Billingham's Three Postulates for GVHD Pathogenesis

In 1966, Rupert Billingham established the three immutable prerequisites required for the development of graft-versus-host disease:

1. Immunologically Competent Graft: The cellular graft must contain viable, mature, immunocompetent donor T-lymphocytes capable of recognizing foreign antigens and initiating an immune response.
2. Host Histocompatibility Differences: The recipient (host) must express major Human Leukocyte Antigens (HLA) or Minor Histocompatibility Antigens (miHAs) that are foreign to the donor, providing the antigenic targets for alloreactivity.
3. Host Immunoincompetence: The recipient must be incapable of mounting an effective immune response to reject the donor graft, typically achieved via high-dose conditioning chemotherapy and total body irradiation (TBI).

+---------------------------------------------------------------------------------------------------+
|                             BILLINGHAM'S CLASSICAL GVHD POSTULATES                                |
|                                                                                                   |
|   [ 1. Immunocompetent Donor T Cells ] + [ 2. Host Foreign HLA/miHAs ] + [ 3. Suppressed Host ]   |
|                                                  |                                                |
|                                                  v                                                |
|                             [ GRAFT-VERSUS-HOST DISEASE INITIATED ]                               |
+---------------------------------------------------------------------------------------------------+

Chronological Classification: Classic vs. Late-Onset vs. Overlap GVHD

Historically, a strict 100-day cutoff separated acute GVHD (<= 100 days) from chronic GVHD (> 100 days). The NIH Consensus Conference modernized these definitions based on clinical and pathological features rather than arbitrary calendar dates:

• Classic Acute GVHD: Diagnostic manifestations of acute GVHD (erythematous maculopapular rash, cholestatic hyperbilirubinemia, secretory diarrhea/nausea) occurring <= 100 days post-transplant.
• Persistent, Recurrent, or Late-Onset Acute GVHD: Diagnostic features of acute GVHD occurring > 100 days post-transplant, typically following reduced-intensity conditioning (RIC), delayed donor leukocyte infusions (DLI), or rapid withdrawal of post-transplant immunosuppression. Lacks diagnostic features of chronic GVHD.
• Overlap Syndrome: Concurrent presence of both acute GVHD manifestations (e.g., active erythematous rash, severe diarrhea, elevated bilirubin) and diagnostic features of chronic GVHD (e.g., cutaneous sclerosis, lichenoid oral changes, fasciitis, keratoconjunctivitis sicca).

---

2. The Ferrara 3-Phase Pathophysiological Model

The immunopathogenesis of acute GVHD follows a coordinated, three-phase biological cascade initially synthesized by James Ferrara and colleagues. This model highlights how pre-transplant conditioning tissue damage primes the host immune microenvironment for subsequent donor T-cell mediated cytotoxicity.

+---------------------------------------------------------------------------------------------------+
|                             THE FERRARA 3-PHASE aGVHD CASCADE                                     |
|                                                                                                   |
|   PHASE 1: AFFERENT TISSUE DAMAGE                                                                 |
|   Chemo / TBI Conditioning ---> Endothelial & Epithelial Lysis ---> Mucosal Barrier Breakdown      |
|                                 * DAMPs (ATP, HMGB1, Heparan Sulfate, Uric Acid)                  |
|                                 * PAMPs (LPS / Endotoxin Translocation across Gut)                |
|                                                  |                                                |
|                                                  v                                                |
|   PHASE 2: ALLOREACTIVE T-CELL PRIMING & EXPANSION                                                |
|   Host & Donor APC Activation (Dendritic Cells / Macrophages) ---> Upregulate MHC & CD80/CD86     |
|                                 * Donor CD4+ & CD8+ T-Cell Allorecognition of Host Antigens       |
|                                 * Clonal Proliferation & Th1/Th17 Polarization                    |
|                                 * IL-2, IL-12, IL-23, IFN-gamma Release (Treg Suppression)        |
|                                                  |                                                |
|                                                  v                                                |
|   PHASE 3: EFFERENT TARGET TISSUE DESTRUCTION                                                     |
|   Cytotoxic T-Cell Migration (CCR9, alpha4beta7 -> Gut; CCR4, CLA -> Skin)                         |
|                                 * Perforin / Granzyme B Mediated Cell Lysis                       |
|                                 * Fas / FasL (CD95/CD95L) Apoptotic Signaling                     |
|                                 * Cytokine Storm Amplification (TNF-alpha, IFN-gamma, IL-1, IL-6) |
|                                 * Target Organ Crypt & Keratinocyte Apoptosis                     |
+---------------------------------------------------------------------------------------------------+

Phase 1: Afferent Phase — Conditioning-Induced Host Tissue Damage

1. Tissue Destruction: Preparative conditioning regimens (high-dose alkylating agents, busulfan, fludarabine, total body irradiation) cause extensive DNA damage and apoptotic lysis of host tissues, particularly rapidly dividing cells in the gastrointestinal mucosa, vascular endothelium, and skin.
2. DAMP and PAMP Release:
   • Danger-Associated Molecular Patterns (DAMPs): Necrotic cells release endogenous intracellular danger molecules, including high-mobility group box 1 (HMGB1), adenosine triphosphate (ATP), uric acid crystals, and extracellular matrix fragments (heparan sulfate, hyaluronan).
   • Pathogen-Associated Molecular Patterns (PAMPs): Conditioning damages the gastrointestinal mucosal barrier, permitting systemic translocation of luminal bacteria, lipopolysaccharide (LPS / endotoxin), and flagellin from the gut microbiota into the lamina propria and mesenteric lymph nodes.
3. Innate Receptor Activation: DAMPs and PAMPs bind host pattern recognition receptors, specifically Toll-Like Receptors (TLR4 for LPS, TLR9 for bacterial DNA) and NOD-like receptors (NLRP3 inflammasome), triggering a massive wave of proinflammatory cytokines: Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 beta (IL-1beta), and Interleukin-6 (IL-6).

Phase 2: Central Priming Phase — APC Activation & Donor T-Cell Proliferation

1. Antigen-Presenting Cell (APC) Activation: Proinflammatory cytokines and TLR engagement activate both host and donor APCs (dendritic cells, monocytes, macrophages). APCs upregulate Major Histocompatibility Complex (MHC) Class I and II molecules, along with critical costimulatory ligands (CD80 [B7-1] and CD86 [B7-2]).
2. T-Cell Allorecognition: Infused mature donor T cells recognize recipient antigens presented by APCs:
   • Direct Allorecognition: Donor T-cell receptors (TCRs) directly bind intact recipient MHC molecules on host APCs.
   • Indirect Allorecognition: Recipient minor histocompatibility antigens (miHAs) are processed and presented by donor APCs on donor MHC molecules.
3. Costimulation & Activation: Signal 1 (TCR binding to peptide-MHC) and Signal 2 (costimulatory CD28 on T cells binding CD80/CD86 on APCs) drive intracellular signaling cascades via calcineurin and NFAT, inducing high-level Interleukin-2 (IL-2) secretion and upregulating the high-affinity IL-2 receptor (CD25 / IL-2R-alpha).
4. Clonal Polarization: Donor T cells undergo rapid clonal expansion and differentiate into effector subsets:
   • Th1 / Tc1 Cells: Driven by IL-12; secrete high concentrations of Interferon-gamma (IFN-gamma) and IL-2.
   • Th17 Cells: Driven by IL-6, TGF-beta, and IL-23; secrete IL-17A, IL-21, and IL-22, mediating severe gut mucosal barrier disruption.
   • Regulatory T-Cell (Treg) Depletion: The highly inflammatory milieu suppresses immunosuppressive CD4+CD25+FoxP3+ regulatory T cells, removing natural immune checkpoints.

Phase 3: Efferent Phase — Effector Trafficking & Target Organ Apoptosis

1. Organ-Specific Homing: Activated effector T cells upregulate specialized chemokine receptors and integrin adhesion molecules directing them to specific target tissues:
   • Gut Homing: Mediated by integrin alpha4beta7 (binding MAdCAM-1 on intestinal venules) and chemokine receptor CCR9 (binding CCL25 in the small intestine).
   • Skin Homing: Mediated by Cutaneous Lymphocyte Antigen (CLA) and chemokine receptors CCR4 and CCR10.
2. Direct Cytotoxic Effector Mechanisms: In target tissues, donor cytotoxic CD8+ T lymphocytes (CTLs) and Natural Killer (NK) cells induce target epithelial and endothelial apoptosis via two primary contact-dependent pathways:
   • Perforin / Granzyme B Pathway: Release of perforin creates transmembrane pores in target cells, allowing granzymes to enter and directly cleave intracellular caspases (Caspase-3, Caspase-8), initiating rapid apoptosis.
   • Fas / FasL (CD95 / CD95L) Pathway: Engagement of Fas ligand on donor T cells with Fas (CD95) death receptors on host epithelial cells activates the extrinsic caspase cascade.
3. Cytokine Storm Amplification: Inflammatory cytokines act synergistically with cellular effectors. TNF-alpha directly induces enterocyte and keratinocyte necrosis, enhances endothelial permeability, and upregulates adhesion molecules. IFN-gamma stimulates macrophages to release nitric oxide and additional TNF-alpha, creating an auto-amplifying cycle of tissue destruction.

---